PulseSight Therapeutics is actively progressing a promising pipeline of novel non-viral minimally-invasive gene therapies. The company's focus is on addressing the unmet needs for treating severe retinal diseases that can lead to blindness. PulseSight Therapeutics specifically targets conditions such as age-related macular degeneration (AMD), including wet AMD and late-stage dry AMD or Geographic atrophy (GA). The development ...
PulseSight Therapeutics is actively progressing a promising pipeline of novel non-viral minimally-invasive gene therapies. The company's focus is on addressing the unmet needs for treating severe retinal diseases that can lead to blindness. PulseSight Therapeutics specifically targets conditions such as age-related macular degeneration (AMD), including wet AMD and late-stage dry AMD or Geographic atrophy (GA). The development of these gene therapies aims to provide innovative and effective solutions for severe retinal diseases that currently lack satisfactory treatments.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.